Trial | NCT00215878  Report issue

Official Title

D-serine for Posttraumatic Stress Disorder Treatment

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    d-serine ...

  • Study Participants

    22
The aim of this study is to asses the effects of the NMDA receptor full agonist D-serine while used as adjuvant treatment for individuals suffering from chronic posttraumatic stress disorder (PTSD). Dysfunction of neurotransmission mediated at NMDA receptor plays a cardinal role in the pathophysiology of PTSD and PTSD patients typically suffer from cognitive dysfunctions and avoidance& depressive symptomatology that may be mediated by NMDA receptor function deficits.

Thus, enhancement of NMDA activity by using D-serine may be beneficial in the treatment of PTSD. The study design involves two 6 week periods during which the participants will be randomly assigned to receive treatment with D-serine (~2g /dy)and placebo. This design allows each participant the opportunity to respond to the experimental treatment.
Study Started
Aug 31
2003
Primary Completion
May 31
2008
Study Completion
May 31
2008
Last Update
Jul 09
2012
Estimate

Drug D-serine (~2g /day)

Two 6 weeks treatment arms under a cross over design. In one arm adjuvant treatment with experimental medication (D-serine ~2g /day), in the second arm adjuvant treatment with placebo (~2g /day)

1 Placebo Comparator

Adjuvant 6 weeks treatment with placebo (~2g /day)

2 Experimental

Adjuvant 6 weeks treatment with D-serine (~2g /day)

Criteria 

Inclusion Criteria:

• Chronic PTSD (DSM-IV diagnosis)

Exclusion Criteria:

Other psychiatric diagnosis
Substance abuse
Unstable medical condition
No Results Posted